Evolus Shares Rise on Jump in Revenue

Dow Jones

Jan 21, 2025

By Don Nico Forbes

Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.

Shares were up 16% in premarket trading at $12.20.

The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.

"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva," said Chief Executive David Moatazedi.

Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.

The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days.

Write to Don Nico Forbes at don.forbes@wsj.com

(END) Dow Jones Newswires

January 21, 2025 09:12 ET (14:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505276857"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505276857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505276857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505276857","market":"sh","top_or_hot":-1,"title":"Evolus Shares Rise on Jump in Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Shares Rise on Jump in Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Shares Rise on Jump in Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-21 22:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505276857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505276857","pubTimestamp":1737468720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.Shares were up 16% in premarket trading at $12.20.The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.\"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi.Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form a","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc."},"translate_title":"Evolus股价因收入增长而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"By Don Nico Forbes \n\n\n \n\n\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n\n\n  Shares were up 16% in premarket trading at $12.20. \n\n\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n\n\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n\n\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n\n\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n\n\n \n\n\n  Write to Don Nico Forbes at don.forbes@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 09:12 ET (14:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}